ＥＧＦＲの阻害剤およびその使用法 - Dana Faber Cancer Institute, Incorporated

Title:

ＥＧＦＲの阻害剤およびその使用法

Document Type and Number:

Japanese Patent JP2021514400

Kind Code:

A

Abstract:

本願は、ＥＧＦＲの活性を調節する、式Ｉａもしくは式Ｉｂを有する化合物、または、その薬剤的に許容できる塩、水和物、もしくは溶媒和物、上記の化合物を含む医薬組成物、および、ＥＧＦＲが関与する疾患を治療または予防する方法、に関する。

More Like This:

WO/2019/245047	NOVEL COMPOUND BINDING TO DESIGNER RECEPTOR, IMAGING METHOD FOR DESIGNER RECEPTOR, AGONIST OR ANTAGONIST, THERAPEUTIC AGENT, COMPANION DIAGNOSTIC AGENT, AND IMAGING METHOD FOR NERVE CELL
JPH04288064	TRICYCLIC HEATEROCYCLE COMPOUND, ITS PRODUCTION AND MEDICINAL PREPARATION WHICH CONTAINS THE COMPOUND AND HAS ANTIHYPERALGESIC PROPERTY

Inventors:

Nathaniel S. Gray
Doris de Clerc
Jebon Jean
Pasi Jeanne
Cilic To
Michael Ek
Eunyoung Park
David Hepner

Application Number:

JP2020566548A

Publication Date:

June 10, 2021

Filing Date:

February 20, 2019

Export Citation:

Click for automatic bibliography generation Help

Assignee:

Dana Faber Cancer Institute, Incorporated

International Classes:

C07D243/38; A61K31/551; A61K45/00; A61P35/00; A61P43/00; C07D403/04

Domestic Patent References:

JP2012511054A	2012-05-17
JP2021514399A	2021-06-10
JP2015205911A	2015-11-19

Foreign References:

US20070105835A1	2007-05-10
WO2014160430A1	2014-10-02
WO2015196072A2	2015-12-23
WO2017177092A1	2017-10-12
US20040254159A1	2004-12-16
WO2006061126A2	2006-06-15
WO2012045194A1	2012-04-12
WO2009124399A1	2009-10-15
WO2017024317A2	2017-02-09
WO2017185023A1	2017-10-26

Other References:

MASTALERZ, HAROLD ET AL.: "Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. (2007), 17(10), 2828-2833, JPN6023003317, 2007, ISSN: 0004975939

Attorney, Agent or Firm:

Yasuhiko Murayama
Shinya Mitsuhiro
Tatsuhiko Abe

Previous Patent: ＥＧＦＲの阻害剤およびその使用法

Next Patent: タンパク質アルギニンメチルトランスフェラーゼ５（ＰＲＭＴ５）の阻害�...